Merit Medical (MMSI) shares soared 8.3% in the last trading session to close at $95.79. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 10.1% loss over the past four weeks.The upside can be attributed to relief-rally across global markets following the announcement of a 90-day pause on tariff hike by the United States.This maker of disposable medical devices is expected to post quarterly earnings of $0.75 per share in its upcomin ...

Company Overview - Merit Medical Systems, Inc. is a global leader in healthcare technology, founded in 1987, focusing on the development, manufacture, and distribution of proprietary disposable medical devices for interventional, diagnostic, and therapeutic procedures, particularly in cardiology, radiology, oncology, critical care, and endoscopy [7]. Product Launch - The company announced the US commercial release of its Ventrax Delivery System, which is the latest addition to its electrophysiology (EP) and cardiac rhythm management (CRM) portfolio [1][2]. Product Features - The Ventrax Delivery System is designed to facilitate the placement of devices used in ablation procedures for treating ventricular tachycardia (VT), a condition that contributes to a significant number of sudden cardiac deaths in the US, estimated between 184,000 and 450,000 annually [3]. - Key features of the Ventrax system include a 95-cm sheath for accessing target locations, an ultralow-profile transition for smooth insertion, and an angled tip to enhance the reach of an ablation catheter [6]. Market Context - VT ablation is one of the fastest-growing areas in electrophysiology, with many physicians adopting retrograde aortic access for VT procedures, indicating a rising demand for effective access tools in this field [7].

Novel all-in-one retrograde aortic access delivery system supports streamlined treatment of ventricular tachycardiaSOUTH JORDAN, Utah, April 09, 2025 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a global leader in healthcare technology, today announced the US commercial release of its Ventrax Delivery System. The new delivery system is Merit’s latest addition to its growing electrophysiology (EP) and cardiac rhythm management (CRM) portfolio. The portfolio provides a unique selection of s ...

Financial Results Announcement - Merit Medical Systems, Inc. will release its financial results for the quarter ended March 31, 2025, after the stock market closes on April 24, 2025 [1] - An investor conference call is scheduled for the same day at 5:00 p.m. Eastern [1] Accessing the Conference Call - Pre-registration is required to access the conference call, with confirmation and dial-in details provided to registrants [2] - A live webcast and slide deck will be available for viewing [2] Company Overview - Merit Medical Systems, Inc. was founded in 1987 and specializes in the development, manufacture, and distribution of proprietary medical devices for various medical procedures [3] - The company operates in fields such as cardiology, radiology, oncology, critical care, and endoscopy, serving customers globally with a sales force and clinical support team of over 800 individuals [3] - Merit employs approximately 7,300 people worldwide [3]

Endoscopic anti-reflux therapy recognized as evidence-based approach to providing relief of GERD symptoms.SOUTH JORDAN, Utah, March 27, 2025 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a global leader of healthcare technology, announced today that the American Society for Gastrointestinal Endoscopy (ASGE) updated its guideline on the diagnosis and management of gastroesophageal reflux disease (GERD) to include Transoral Incisionless Fundoplication (TIF 2.0) and TIF 2.0 Consecutive Transo ...

Merit Medical Systems (MMSI) released 12-month efficacy results for its WRAPSODY Cell-Impermeable Endoprosthesis (“CIE”), demonstrating strong performance in vascular access maintenance. Designed to enhance long-term outcomes for patients with end-stage renal disease, WRAPSODY CIE leverages advanced technology to improve vessel patency and reduce complications.This milestone underscores Merit Medical's dedication to innovation in interventional medicine. With promising clinical data, WRAPSODY CIE reinforces ...

Core Insights - Merit Medical Systems, Inc. announced the upcoming publication of six-month results from the WRAPSODY Arteriovenous Access Efficacy (WAVE) trial in Kidney International and the twelve-month results will be presented at the Society of Interventional Radiology's 50th Annual Scientific Meeting [1][2] Group 1: Trial Overview - The WAVE trial is a multicenter, international investigational device exemption (IDE) trial evaluating the safety and efficacy of the WRAPSODY CIE over two years, involving 245 hemodialysis patients with venous outflow stenosis [3] - The trial compares the WRAPSODY CIE treatment (n=122) against standard percutaneous transluminal angioplasty (PTA, n=123) [3] Group 2: Efficacy and Safety Results - At six months, the WRAPSODY CIE demonstrated a target lesion primary patency of 89.8% compared to 62.8% for PTA (p<0.0001) and an access circuit primary patency of 72.6% versus 57.9% for PTA (p=0.015) [6] - At twelve months, the WRAPSODY CIE maintained a target lesion primary patency of 70.1% compared to 41.6% for PTA (p<0.0001) and an access circuit primary patency of 58.1% versus 34.4% for PTA (p=0.0003) [6][9] - No significant difference in safety outcomes was observed between the WRAPSODY CIE and PTA [6] Group 3: Regulatory Approval and Commercialization - The WRAPSODY CIE received premarket approval (PMA) from the FDA in December 2024 and began commercialization in the U.S. in January 2025 [7] - The device has also received the Conformité Européenne (CE) Mark for commercial use in the European Union and is available in Brazil [7] Group 4: Company Background - Merit Medical Systems, Inc. was founded in 1987 and specializes in the development, manufacture, and distribution of proprietary medical devices for interventional, diagnostic, and therapeutic procedures [10] - The company employs approximately 7,400 people worldwide and has a sales force and clinical support team of over 800 individuals [10]

SOUTH JORDAN, Utah, March 18, 2025 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a global leader of healthcare technology, announced that Chairman and Chief Executive Officer, Fred Lampropoulos, will visit the Nasdaq MarketSite in Times Square to ring the opening bell on Wednesday, March 19, 2025. The ceremony begins at 9:15 A.M. (EDT) and the bell ringing takes place at 9:30 A.M. "Merit’s listing on Nasdaq for 35 years marks a significant milestone in our company’s history,” said Lampropo ...

Group 1 - Medical technology companies have experienced a "flight to safety" in 2025, benefiting from increased investor interest [1] - Merit Medical (NASDAQ: MMSI) has outperformed the market, with shares rising nearly 20% since the last analysis [1]

Company Overview - Merit Medical Systems, Inc. (MMSI) has initiated the enrollment of the first patient in its multicenter, prospective PREEMIE study for the Bloom Micro Occluder System aimed at treating patent ductus arteriosus (PDA) in premature infants [1][2] - The Bloom Micro Occluder System is currently not approved for PDA treatment [1] Study Details - The PREEMIE study plans to enroll at least 55 premature infants with significant PDA across up to 10 U.S. study sites, targeting infants weighing between 600 g and 2,500 g [2] - The study will evaluate the safety and efficacy of the device over a six-month period as part of the premarket approval (PMA) application [2][4] Significance of the Study - PDA is a common congenital heart condition in premature infants, and the Bloom Micro Occluder System is designed as a minimally invasive treatment option [4] - An expert noted that there is currently no approved device for treating PDA in infants weighing 600 grams, making this study crucial for this high-risk population [5] Management Expectations - Merit Medical's management anticipates that the PREEMIE study will significantly enhance care for vulnerable premature infants who could benefit from PDA closure using a transcatheter device [6] Industry Prospects - The global PDA treatment market was valued at $2.4 billion in 2022 and is projected to reach $7.34 billion by 2030, growing at a CAGR of 15% [7] - The increasing demand for diagnostic tests and the rising incidence of PDA in infants are expected to drive market growth, positioning Merit Medical favorably within this niche [7] Recent Developments - Merit Medical reported robust revenue growth in its Cardiovascular unit in its fourth-quarter 2024 results [8] - The company received FDA PMA approval for the WRAPSODY Cell-Impermeable Endoprosthesis, allowing for commercialization in 2025 [8] - Positive six-month findings from the WAVE pivotal trial for the WRAPSODY device were also announced [9] Competitive Landscape - Boston Scientific Corporation (BSX) has entered into an agreement to acquire SoniVie Ltd. to expand its offerings in interventional cardiology [10] - AngioDynamics, Inc. (ANGO) has initiated a randomized study for the Auryon Atherectomy System [12] - Medtronic plc (MDT) released positive two-year results from the SMART Trial, showcasing its competitive position in the cardiovascular space [13]